BlackRock
CUE icon

BlackRock’s Cue Biopharma CUE Stock Holding History

BlackRock’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$103K Hold
14,972
– – ﹤0.01% 4953
2025
Q4 		$137K Hold
14,972
– – ﹤0.01% 4820
2025
Q3 		$323K Hold
14,972
– – ﹤0.01% 4568
2025
Q2 		$306K Sell
14,972
-6,201
-29% -$132K ﹤0.01% 4567
2025
Q1 		$579K Sell
21,173
-125
-0.6% -$4.64K ﹤0.01% 4361
2024
Q4 		$696K Buy
21,298
+2,265
+12% +$85.1K ﹤0.01% 4328
2024
Q3 		$432K Sell
19,033
-6,192
-25% -$134K ﹤0.01% 4364
2024
Q2 		$938K Sell
25,225
-49,578
-66% -$2.45M ﹤0.01% 4196
2024
Q1 		$4.24M Sell
74,803
-3,156
-4% -$223K ﹤0.01% 3738
2023
Q4 		$6.17M Buy
77,959
+6,994
+10% +$500K ﹤0.01% 3605
2023
Q3 		$4.9M Buy
70,965
+2,096
+3% +$205K ﹤0.01% 3665
2023
Q2 		$7.54M Buy
68,869
+46,721
+211% +$5.49M ﹤0.01% 3551
2023
Q1 		$2.37M Sell
22,148
-1,258
-5% -$120K ﹤0.01% 3973
2022
Q4 		$2M Sell
23,406
-2,551
-10% -$233K ﹤0.01% 4135
2022
Q3 		$1.74M Sell
25,957
-1,774
-6% -$153K ﹤0.01% 4260
2022
Q2 		$2.07M Sell
27,731
-51,645
-65% -$6.04M ﹤0.01% 4239
2022
Q1 		$11.6M Buy
79,376
+3,034
+4% +$643K ﹤0.01% 3498
2021
Q4 		$25.9M Buy
76,342
+4,327
+6% +$1.67M ﹤0.01% 3126
2021
Q3 		$31.5M Buy
72,015
+388
+0.5% +$135K ﹤0.01% 2976
2021
Q2 		$25M Sell
71,627
-3,296
-4% -$1.28M ﹤0.01% 3159
2021
Q1 		$27.4M Buy
74,923
+2,824
+4% +$1.16M ﹤0.01% 3005
2020
Q4 		$27.1M Buy
72,099
+1,577
+2% +$630K ﹤0.01% 2848
2020
Q3 		$31.8M Buy
70,522
+6,130
+10% +$3.53M ﹤0.01% 2577
2020
Q2 		$47.3M Buy
64,392
+20,078
+45% +$14.5M ﹤0.01% 2280
2020
Q1 		$18.9M Sell
44,314
-1,942
-4% -$942K ﹤0.01% 2637
2019
Q4 		$22M Buy
46,256
+5,547
+14% +$1.74M ﹤0.01% 2821
2019
Q3 		$10.3M Buy
40,709
+2,438
+6% +$586K ﹤0.01% 3195
2019
Q2 		$10.3M Buy
38,271
+6,733
+21% +$1.67M ﹤0.01% 3240
2019
Q1 		$7.31M Buy
31,538
+1,441
+5% +$274K ﹤0.01% 3253
2018
Q4 		$4.24M Sell
30,097
-187
-0.6% -$33.9K ﹤0.01% 3447
2018
Q3 		$8.22M Buy
30,284
+885
+3% +$256K ﹤0.01% 3325
2018
Q2 		$10.5M Buy
29,399
+16,238
+123% +$6.46M ﹤0.01% 3218
2018
Q1 		$5.55M Buy
+13,161
New +$6M ﹤0.01% 3385

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
GWMR
GC Wealth Management RIA Cambridge, Massachusetts $1.73B AUM 16.14% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $1.84B AUM 19.34% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return

BlackRock's CUE Position: Q1 2026 in Review

BlackRock held its Cue Biopharma (CUE) position steady in Q1 2026 at 14,972 shares worth $103K. The position accounts for ﹤0.01% of the portfolio, ranked #4953.

BlackRock first reported a position in CUE in Q1 2018 and has held it in 33 quarters since. The position peaked at $47.3M in Q2 2020. 55 funds tracked by Wall St. Rank hold CUE as of Q1 2026.

  • BlackRock held 14,972 shares of Cue Biopharma worth $103K as of Q1 2026.
  • BlackRock left its Cue Biopharma share count unchanged in Q1 2026.
  • Cue Biopharma made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #4953 holding.
  • BlackRock first reported a position in Cue Biopharma in Q1 2018 and has held it in 33 quarters since.
  • BlackRock's Cue Biopharma position peaked at $47.3M in Q2 2020.
  • 55 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.